Science & Innovation

Pipeline

Dorzagliatin

mGluR5

Poster and Presentation

Peer Reviewed Publications

Announcements and Circulars

Listing Documents

Investor Presentation

IR Contact

Investor Calendar

Stock Information (2552.HK)

Corporate Communications

Portfolio Advisory Board

Senior Scientific Advisory Board

Our Science

> Our Science

> Peer Reviewed Publications

Poster and Presentation

Peer Reviewed Publications

2021 August, Clinical and Translational Science: Effect of renal impairment on the pharmacokinetics and safety of dorzagliatin, a novel dual-acting glucokinase activator.

Clinical and Translational Science

Nov 07, 2022

Return list

2022 May, Nature Medicine: Dorzagliatin in drug-naïve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial

2020 June / Meta-analysis of the epidemiology of microvascular complications in people with Type 2 diabetes in mainland China

About Us

Company Overview

Company History

Leadership Team

Portfolio Advisory Board

Senior Scientific Advisory Board

Partner

Media center

Research & Development

Inovation

Pipeline

Dorzagliatin

mGluR5

Company Publications

Peer Reviewed Publications

Investor Relations

Corporate Governance

Financial Report

Announcements & Circulars

Listing Documents

Investor Presentation

IR Contact

Investor Calendar

Stock information

Media

Company News

Media Releases

Video

Careers

Culture

Join Us

Product

HuaTangNing(华堂宁®)

Focus Us

沪公网安备 31011502013809号 Privacy Statement Terms of Use

How we use cookies

Hua Medicine uses cookies to enable and improve the use of the website. By continuing to use the site, you consent to the use of these cookies. To learn more about cookies, please read our privacy statement.